HPLC analysis of K-48 concentration in plasma

Area of Science:

• Pharmacology
• Analytical Chemistry
• Toxicology

Background:

• Organophosphorus compounds pose a significant toxicological threat.
• Oximes are critical in reactivating inhibited enzymes during organophosphorus poisoning.
• Pralidoxime is a commonly used oxime, but its efficacy can be limited.

Purpose of the Study:

• To evaluate K-48, a new oxime-type compound, as a potential enzyme reactivator.
• To determine the plasma concentration of K-48 using a validated analytical method.
• To compare the pharmacokinetic profile of K-48 with pralidoxime.

Main Methods:

• Reversed-phase high-performance liquid chromatography (HPLC) with octyl silica stationary phase and UV detection was employed.
• Plasma concentrations of K-48 were analyzed after intramuscular administration.
• Pharmacokinetic parameters, including dose-normalized area under the curve (AUC) and elimination kinetics, were assessed.

Main Results:

• A fast and simple HPLC method was established for K-48 quantification.
• K-48 exhibited a relatively high dose-normalized AUC compared to pralidoxime.
• Following intramuscular administration, K-48 elimination between 15 and 120 minutes followed zero-order kinetics.

Conclusions:

• K-48 demonstrates favorable pharmacokinetic properties, suggesting its potential as an effective antidote for organophosphorus exposure.
• The high dose-normalized AUC of K-48 may offer therapeutic advantages.
• Zero-order elimination kinetics indicate predictable drug levels over time.